Navigating Complexity in the Post-CDK4/6 Inhibitor Treatment Setting for Patients With ER+/HER2- mBC: Strategies for Optimally Integrating Next-Generation Oral SERDs
Navigating Complexity in the Post-CDK4/6 Inhibitor Treatment Setting for Patients With ER+/HER2- mBC: Strategies for Optimally Integrating Next-Generation Oral SERDs
ActionED
The management of hormone receptor–positive (HR-positive), human epidermal growth factor receptor 2–negative (HER2-negative) metastatic breast cancer (mBC) is undergoing rapid transformation, largely driven by the imperative to overcome acquired endocrine resistance, frequently mediated by somatic estrogen receptor 1 (ESR1) mutations. These mutations predict a lack of benefit from further aromatase inhibitor (AI) therapy, making the correct identification and subsequent targeting of these alterations critical for guiding treatment selection. Next-generation oral selective estrogen receptor degraders (SERDs) offer improved efficacy and enhanced estrogen receptor (ER)-degrading potential, especially in ESR1-mutated tumors, thus positioning them as crucial options in the post-cyclin-dependent kinase 4/6 (CDK4/6) inhibitor setting. However, data from the 2025 RETRACT survey revealed that next-generation sequencing (NGS) remains underutilized in mBC patients and that significant variability exists in therapeutic decision-making, indicating the need for clear, evidence-informed guidance on post–CDK4/6 inhibitor treatment sequencing.
To address these gaps in testing and treatment, and ensure that clinicians can effectively evaluate the mechanisms of action and efficacy data of new and emerging next-generation SERDs, this educational activity utilizes the RE-AIM training and implementation model to 1) facilitate peer-to-peer learning at the point of care around novel and emerging oral SERDs and oral SERD combinations; and 2) build the appropriate infrastructure, clinical capacity, and training in oncology practices to optimally adopt these novel therapies in patients with estrogen receptor-positive/HER2-negative mBC.
Faculty: Erica L. Mayer, MD, MPH, FASCO; Nan Chen, MD; Jodi Taraba, PharmD M.Sc., BCOP
Release Date:
Expiration Date: July 31, 2027
